Tolcapone in Parkinson's disease: Liver toxicity and clinical efficacy

Expert Opinion on Drug Safety

Volumn 4, Issue 1, 2005, Pages 69-73

  Borges, Nuno ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Catechol O methyltransfese (COMT); Entacapone; Liver toxicity; Parkinson's disease (PD); Safety; Tolcapone

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; TOLCAPONE;

CAUSE OF DEATH; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INFORMATION; DRUG LABELING; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; EUROPE; HEPATITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; MITOCHONDRIAL RESPIRATION; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PATIENT MONITORING; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT FAILURE;

ADENOSINE TRIPHOSPHATE; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; HALF-LIFE; HEPATITIS, TOXIC; HUMANS; LEVODOPA; LIVER; MITOCHONDRIA; NITROPHENOLS; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHORYLATION; SAFETY;

EID: 12544253962     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.1.69     Document Type: Review

References (41)

1. HORNYKIEWICZ O: Biochemical aspects of Parkinson's disease. Neurology (1998) 51:S2-S9.
2. NUTT JG: Long-term L-DOPA therapy challenges to our understanding and for the care of people with Parkinson's disease. Exp. Neurol. (2003) 184:9-13.
3. SAMII A, LETWIN SR, CALNE DB: Prospects for new drug treatment in idiopathic parkinsonism. Drug Discov. Today (1998) 3:131-140.
4. KURTH MC, ADLER CH: COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology (1998) 50:S3-14.
5. LEWITT PA: New drugs for the treatment of Parkinson's disease. Pharmacotherapy (2000) 20:26S-32S.
6. LUDIN HP: [Modern therapeutic possibilities in Parkinson's disease]. Schweiz Med. Wochenschr. (1999) 129:741-747.
7. MANNISTO PT, ULMANEN I, LUNDSTROM K et al.: Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. (1992) 39:291-350.
8. NUTT JG: Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet (1998) 351 1221-1222.
9. GOMES P, SOARES-DA-SILVA P: Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothetial cells. Neuropharmacology (1999) 38 1371-1380.
10. RECHES A, MIELKE LR, FAHN S: 3-O-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology (1982) 32:887-888.
11. DUPONT E, BURGUNDER JM, FINDLEY LJ, OLSSON JE, DORFLINGER E: Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's disease Study Group II (TIPS II). Mov. Disord. (1997) 12:928-934.
12. KAAKKOLA S, GORDIN A, MANNISTO PT: General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmacol. (1994) 25:813-824.
13. KAAKKOLA S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs (2000) 59:1233-1250.
14. ROBERTS JW, CORA-LOCATELLI G, BRAVI D et al.: Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology (1993) 43:2685-2688.
15. SPENCER CM, BENFIELD P: Tolcapone. CNS Drugs (1996) 5:475-481.
16. WATERS CH, KURTH M, BAILEY P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long- term treatment. The Tolcapone Stable Study Group. Neurology (1997) 49 665-671.
17. GORDIN A, REINIKAINEN K, DURIF F: Effiect of entacapone on quality of life in Parkinson's disease. J. Am. Geriatr. Soc. (2001) 49:S123-S123.
18. DURIF F, DEVAUX I, PERE JJ, DELUMEAU JC, BOURDEIX I: Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur. Neurol. (2001) 45:111-118.
19. ASSAL F, SPAHR L, HADENGUE, A et al.: Tolcapone and fulminant hepatitis Lancet (1998) 352:958.
20. SPAHR L, RUBBIA-BRANDT L, BURKHARD PR, ASSAL F, HADENGUE A: Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig. Dis. Sci. (2000) 45 1881-1884.
21. COLOSIMO C: The rise and fall of tolcapone. J. Neurol. (1999) 246:880-882.
22. OLANOW CW: Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch. Neurol. (2000) 57:263-267.
23. NO AUTHORS LISTED: European Medicine Evaluation Agency: Recommendation for the suspension of the marketing authorization for Tasmar® (tolcapone). Press Release (1998)
24. NO AUTHORS LISTED: European Medicine Evaluation Agency: EMEA Public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar®). Press Release (2004)
25. ELLISON RH: Dear Healthcare Professional letter regarding appropriate use of Tasmar®. Roche Laboratories Inc. (1998).
26. NO AUTHORS LISTED: New warnings for Parkinson's drug, Tasmar. Food and Drug Administration Talk Paper (1998).
27. BENABOU R, WATERS C: Hepatotoxic profile of catechol-O methyltransferase inhibitors in Parkinson's disease. Expert. Opin. Drug Saf. (2003) 2:263-267.
28. BORGES N: Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. (2003) 26 743-747.
29. NISSINEN E, KAHEINEN P, PENTTILA KE, KAIVOLA J, LINDEN IB: Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur. J. Pharmacol. (1997) 340:287-294.
30. HAASIO K, KOPONEN A, PENTTILA KE, NISSINEN E: Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. (2002) 453:21-26.
31. HAASIO K, LOUNATMAA K, SUKURA A: Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. Exp. Toxicol. Pathol. (2002) 54:9-14.
32. HAASIO K, NISSINEN E, SOPANEN L, HEINONEN EH: Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J. Neural Transm. (2002) 109:1391-1401.
33. KORLIPARA LV, COOPER JM, SCHAPIRA AH: Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology (2004) 46:562-569.
34. HAASIO K, SOPANEN L, VAALAVIRTA L, LINDEN IB, HEINONEN EH: Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J. Neural Transm. (2001) 108:79-91.
35. SMITH KS, SMITH PL, HEADY TN et al.: In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol. (2003) 16:123-128.
36. WIKBERG T, VUORELA A, OTTOILA P, TASKINEN J: Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. (1993) 21 81-92.
37. ACUÑA G, FOERNZLER D, LEONG D et al.: Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. (2002) 2:327-334.
38. FISHER A, CROFT-BAKER J, DAVIS M, PURCELL P, MCLEAN AJ: Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov. Disord. (2002) 17:1362-1365.
39. BECK S, HUBBLE J, REINIKAINEN K: Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov. Disord. (2002) 17 1397-1399.
40. ONOFRJ M, THOMAS A, IACONO D, DI IORIO A, BONANNI L: Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol. (2001) 46:11-16.
41. SHEPHERD J, CLEGG A: Entacapone as an adjunctive treatment to levodopa in Parkinson's disease. Wessex Institute for Health Research and Development. Development and Evaluation Committee Report No. 104 (1999).